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Objectives: To establish if the procalcitonin (PCT) test’s diagnostic performance 
is more clinically and cost-effective than C reactive protein (CRP) and White 
Cell Count (WCC) tests for suspicion of prodomal stage Meningococcal disease 
(MD) in children presenting at emergency department (ED) with a fever without 
source. MethOds: A decision analytic model was designed to reflect realistic 
clinical pathways for a child presenting with non-specific fever to ED. Test accu-
racy was evaluated using data from independent studies carried out in developed 
countries identified through a systematic literature search. Studies were combined 
to determine the optimal cut-off value for the PCT, CRP and WCC tests, each as an 
indicator of MD. Summary Receiver Operator Curve (SROC) analysis was used to 
determine the inter-study and overall diagnostic performance of each test from 
the areas under the curve (AUC), with 95% confidence intervals (CIs). Components 
of each clinical pathway were costed in UK sterling using the National Schedule 
of Reference Costs 2010-2011. Hospital stays were costed using the appropriate 
Health Resource Group code. Results: Seven studies involving 881 children with 
non-specific fever provided data for inclusion. The PCT test was more accurate 
(sensitivity= 89%, 95%CI= 75-96; specificity= 71%, 95%CI= 37-91) for early MD com-
pared to CRP (sensitivity= 84%, 95%CI= 74-90; specificity= 60%, 95%CI= 44-74) and 
WCC (sensitivity= 50%, 95%CI= 39-60; specificity= 68%, 95%CI= 54-79). PCT had the 
best PLR (3.0, 95%CI= 1.8-7.8) to be viable as a rule-in test for MD and a borderline 
NLR as a rule-out test, making it a better option to either CRP (2.1, 95%CI= 1.4-3.1) 
or WCC (1.5, 95%CI= 1.0-2.3). Outcomes from the decision analytic model indicated 
that the PCT test was the most cost-effective (£2547 per patient treated), followed 
by the combined CRP and WCC test (£3069 per patient treated). cOnclusiOns: The 
improved sensitivity and specificity of the PCT test provides a more cost-effective 
test than the currently recommended CRP and WCC tests.
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Objectives: To evaluate the cost-effectiveness of first-line treatment of heavy men-
strual Bleeding (HMB) from the perspective of the Spanish National Healthcare 
System. MethOds: A cost-effectiveness analysis was performed using a Markov 
model to simulate the evolution of a cohort of women in reproductive age, with 
HMB and who wish to preserve their fertility status, in a time horizon of 5 years. 
The treatment strategies were levonorgestrel intrauterine system (LNG-IUS), estra-
diol valerate/dienogest (E2V/DNG), combined oral contraceptives (COC) and oral 
progestins (PROG). Clinical data was modelled indirectly combining literature and 
expert opinion. Outcomes were symptom-free months (SFM), quality-adjusted life 
months (QALM) and costs expressed in € in 2012. A probabilistic sensitivity analy-
sis was conducted to examine the robustness of the results. Results: The mean 
treatment cost of HMB at 6 month was 205€ for LNG-IUS, 318€ for E2V/DNG, 412€ 
COC and 766€ PROG. In the analysis over 5 years, LNG-IUS produced savings of 
578€ compared to E2V/DNG, 991€ compared to COC and 1,821€ compared to PROG. 
Regarding the effectiveness, LNG-IUS provided 51.30 SFM, while E2V/DNG, COC and 
PROG provided 50.64, 49.09 and 47.77 SFM, respectively. Moreover, 77%, 65%, 56% and 
46% of the patients treated with LNG-IUS, E2V/DNG, COC and PROG, respectively, 
continued treatment without surgery during the 5 year period. Considering QALM 
as outcome, LNG-IUS and E2V/DNG were the options that yielded more gains in 
QALM (49.71 for LNG-IUS, 48.09 for E2V/DNG, 46.59 for COC and 44.66 for PROG). 
LNG-IUS was the most effective and less costly, therefore dominant option. In the 
oral treatments comparison, E2V/DNG was dominant, providing savings and gains in 
terms of SFM and QALM. The probabilistic sensitivity analysis on the key parameters 
confirmed the robustness of the base case. cOnclusiOns: LNG-IUS is a cost-saving 
option for the treatment of HMB in Spain. Among oral treatments, E2V/DNG is also 
a dominant strategy.
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Objectives: Brazil is among the countries with the highest incidence of preterm 
births. Incorporation of diagnostic tests to predict a preterm birth could improve 
the efficiency of the clinical practice reducing hospital expenses related to mater-
nal hospitalization. The aim of this study was to compare the cost-effectiveness 
of fibronectin testing (FN) vs cervical length (CL) measurement in women with 
symptomatic preterm labor. MethOds: Systematic review of the literature of the 
diagnostic tests and development of a decision analytic model using the accuracy of 
the diagnostic tests to predict preterm birth and project the results in terms of effec-
tiveness and cost. The analysis was performed for a hypothetical cohort of 10,000 
patients, for each test, with symptomatic preterm labor between 24 and 34 weeks of 
gestation. The primary perspective of the study was of the Brazilian Health system 
(SUS). Data sources were the medical literature, SUS official published prices for 
medicines and DATASUS (SUS database). Costs are in 2012 Brazilian Reais. Results: 
A total of 14 studies were included. There was a wide variation concerning the accu-
racy of the tests among the studies, particularly with respect to gestational age at 
Objectives: To predict the cost of a delivery following assisted reproductive 
technologies (ART) in Poland. Moreover, the cumulated in vitro fertilization (IVF) 
effectiveness ratio was calculated and the costs of drugs for each of the three 
stimulation protocols used in IVF (long with GnRH agonist, short with GnRH 
antagonist and short with GnRH agonist) were estimated. MethOds: In order to 
calculate the IVF effectiveness, a pooled analysis of the results from European IVF 
monitoring reports concerning Poland from 2008 to 2010 was performed. Costs of 
the clinical and biotechnological parts of IVF were based on the Ministry of Health 
calculation. Drugs’ costs were estimated considering both dosages based on the 
Summaries of Products Characteristics and the retail prices. Costs were calculated 
based on identified costs in both the patient and payer perspectives. Results: 
The overall birth rate per cycle was 21,70%. The probability of a delivery was 
1,5 higher during fresh cycle than in frozen embryo transfer. A total of 24,09% 
of embryo transfers resulted in delivery. The cost of drugs used during ovarian 
stimulation protocol was estimated on 6 055 PLN. The average cost per cycle was 13 
565 PLN. Drugs account for 45% of this value. The average cost per birth was 42 848 
PLN. cOnclusiOns: In vitro fertilization is an expensive procedure for a patient 
in Poland. It is due to a limited effectiveness, usually requiring several repeats of 
the whole cycle of IVF with no drugs reimbursement. The ovarian stimulation is 
the most expensive part of the procedure. Thus, reimbursement of medication 
should also be established.
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Objectives: Toxoplasma infection during pregnancy presents a serious hazard 
to the fetus including lifelong disabilities of connatal infected children. This 
foodborne illness is a common burden worldwide. Prevention strategies of the 
health care providers are diverse. In Austria, the maternal toxoplasma screening 
has been implemented four decades ago. The aim of this study was to deter-
mine cost-effectiveness of the maternal toxoplasma screening. MethOds: We 
developed a two arm decision-analytic model. One arm of the model assessed 
the costs and consequences of no prevention, while the other one evaluated 
the screening. The study population included pregnant women and offspring 
screened and treated for toxoplasma infection. The average number of births 
was 76,547 and 50,000 pregnant women were susceptible to infection. The 
analysis focused on lifetime consequences of the connatal infection. This 
encompassed direct costs (screening, cost of illness, maternal and pediatric 
treatment), indirect costs (changed job situation of parents, human-capital of 
dead individuals, blindness and special schools), quality-adjusted-life-years 
(QALYs) and reduced expectation of life. Costs were presented per child and 
for the Austrian birth cohort. Costs from published sources were used (2012 
Euro) from the societal perspective. QALYs, life-years (LYs) and costs were pro-
jected over a life-time horizon and discounted at 3% p.a. Results: Maternal 
toxoplasma screening reduced transmission risk by 40% and one quarter of 
affected children showed symptoms. We found five-times higher lifetime costs 
per child without prevention compared to screening. Also direct costs were 
lower in the latter group; screening costs did not offset costs of sequelae. A split 
in direct and indirect costs components demonstrated that proportion of direct 
costs without prevention amounted to 20% and 95% with screening. Screening 
resulted in QALYs gained and LYs saved. cOnclusiOns: Funding the maternal 
toxoplasma screening saves money and is cost-effective for the society and the 
Austrian health care system.
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Objectives: Rotavirus gastroenteritis is a major health burden in young chil-
dren worldwide. This study investigates the cost-effectiveness of universal pae-
diatric rotavirus vaccination with RIX4414, a two-dose human rotavirus vaccine, 
in Greece. MethOds: A Markov cohort model with a cycle time of one month 
was constructed in Microsoft Excel. The birth cohort of 114,766 infants, based 
on 2010 official registry was entered into the model and followed over average 
life expectancy with acute rotavirus events measured up to five years of age. 
Probabilities, utility scores and costs for hospitalisations, hospital-acquired 
rotavirus infection, medical consultations, emergency visits and deaths due to 
rotavirus were taken from published sources and national databases. Costs and 
benefits were reported at 2012 euros, discounted at 3% and 1.5% respectively 
per year and compared between a vaccinated and unvaccinated cohort from 
a Social Sick-Fund perspective. Results: Vaccination with RIX4414 incurred 
an incremental cost of € 16,569 per QALY at a price of € 48/dose. The estimated 
number of rotavirus-related diarrhoea events per year up to the age of five is 
45,906. Total direct medical cost of rotavirus disease without vaccination is 
around € 8,980,000 per year in Greece. Vaccination (40% coverage) reduces the 
number of gastro-enteritis events by 27% to 33,492 and the number of rotavirus-
related medical visits from 17,214 per year to less than 11,000. Total cost of 
rotavirus disease, including the costs of vaccination, in the vaccinated cohort 
is estimated at € 10,087,614 per year, with a cost reduction on direct medical 
costs of € 3,343,781. This cost reduction reflects the high financial disease burden 
related to the medical visits including paediatricians, emergency and hospital 
visits. cOnclusiOns: Paediatric vaccination against rotavirus with RIX4414 
versus no vaccination in Greece improves health outcomes, reduces direct medi-
cal costs and is cost-effective from a social sick fund perspective.
